Gabapentin Dosing for Refractory Dry Cough
For adults with unexplained chronic cough, start gabapentin at 300 mg once daily and titrate upward by adding one additional 300 mg dose each day as tolerated, up to a maximum of 1800 mg daily in two divided doses. 1
Recommended Dosing Schedule
The American College of Chest Physicians (CHEST) provides the definitive dosing protocol for gabapentin in refractory chronic cough: 1
- Day 1: 300 mg once daily
- Day 2: 300 mg twice daily (600 mg/day total)
- Day 3 onward: Continue adding 300 mg increments daily as tolerated
- Target dose: 1800 mg/day in two divided doses (900 mg twice daily)
- Maximum dose: 1800 mg/day
This differs from the FDA-approved dosing for postherpetic neuralgia (which uses three-times-daily dosing), but the twice-daily regimen is specifically recommended for chronic cough management. 1
Clinical Context and Patient Selection
Gabapentin should only be prescribed after confirming the cough is truly unexplained or refractory: 1
- Cough duration: Must persist >8 weeks
- Prior workup required: Negative testing for bronchial hyperresponsiveness, eosinophilic bronchitis (sputum eosinophils, exhaled nitric oxide), and acid reflux
- Failed treatments: Inadequate response to guideline-directed therapy for common causes (asthma, GERD, postnasal drip)
Evidence Supporting This Approach
The landmark randomized controlled trial by Ryan et al. demonstrated that gabapentin at doses up to 1800 mg/day significantly improved cough-specific quality of life (Leicester Cough Questionnaire improvement of 1.80 points, p=0.004) with a number needed to treat of 3.58. 2 This study forms the basis for the CHEST guideline recommendations. 1
Additional research supports gabapentin's efficacy at the 900 mg/day dose, with one study showing comparable success rates (57.3%) when used for suspected refractory GERD-induced chronic cough. 3 A cohort analysis found that responders typically had higher pre-treatment cough severity scores and history of preceding airway infection. 4
Monitoring and Duration
Critical safety requirement: Discuss potential side effects and risk-benefit profile before initiating therapy, and reassess this profile at 6 months before continuing treatment. 1
Common adverse effects include: 2
- Confusion, dizziness, fatigue (31% in clinical trials)
- Dry mouth and nausea
- Less commonly: blurred vision, headache, memory loss
The side effect profile is generally favorable compared to alternative neuromodulators like baclofen, with gabapentin causing significantly less somnolence (20.5% vs 35.0%) and dizziness (11.1% vs 23.9%). 3
Dose Adjustments for Special Populations
Renal impairment: Dose reduction is mandatory based on creatinine clearance: 5
- CrCl 30-59 mL/min: Maximum 700 mg twice daily
- CrCl 15-29 mL/min: Maximum 700 mg once daily
- CrCl <15 mL/min: Maximum 300 mg once daily
- Hemodialysis: Supplemental post-dialysis dose of 125-350 mg required
Elderly patients: Use caution with dose selection due to age-related decline in renal function; adjust based on creatinine clearance. 5
Treatment Duration and Discontinuation
When gabapentin successfully controls cough, most laryngologists wait 3-6 months before making changes, then either wean to the lowest effective dose (68.3% of practitioners) or taper off completely (24.4%). 6 If cough recurs after weaning, 97.6% of specialists reinitiate the medication, typically at the previously effective dose. 6
Discontinuation protocol: Taper gradually over a minimum of 1 week to avoid withdrawal effects; longer tapering periods may be needed at prescriber discretion. 5
Alternative Considerations
If gabapentin fails at maximum tolerated doses, consider switching to another neuromodulator (amitriptyline is the second most common choice among specialists at 39% first-line use) or proceeding to superior laryngeal nerve block (24.4% of practitioners). 6 The French guidelines also endorse pregabalin, amitriptyline, or morphine as alternatives, ideally combined with speech and/or physical therapy. 7, 8
Common Pitfalls to Avoid
- Inadequate dose titration: Many patients require the full 1800 mg/day for optimal effect; don't abandon therapy prematurely at lower doses if well-tolerated 1
- Prescribing without proper workup: Gabapentin should not be used as first-line therapy before excluding treatable causes 1
- Ignoring renal function: Failure to adjust for renal impairment significantly increases toxicity risk 5
- Inadequate monitoring: The 6-month reassessment is essential given the chronic nature of treatment and potential for adverse effects 1